Stephens Inc Halozyme Therapeutics, Inc. Transaction History

Stephens Inc

$6.84 Billion
Q4 2024

A detailed history of Stephens Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Stephens Inc holds 5,464 shares of HALO stock, worth $333,631. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,464

Previous 6,841 20.13%

Holding current value

$333,631

Previous $391,000 33.25%

% of portfolio

0.0%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 28, 2025	SELL	$42.57 - $61.09 $58,618 - $84,120	-1,377 Reduced 20.13%	5,464 $261,000
Q3 2024 Oct 28, 2024	SELL	$51.3 - $64.42 $120,144 - $150,871	-2,342 Reduced 25.5%	6,841 $391,000
Q2 2024 Aug 06, 2024	SELL	$37.81 - $52.4 $1,361 - $1,886	-36 Reduced 0.39%	9,183 $480,000
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $98,682 - $122,913	2,930 Added 46.59%	9,219 $375,000
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $5,297 - $6,693	159 Added 2.59%	6,289 $232,000
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $9,297 - $11,227	255 Added 4.34%	6,130 $234,000
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $89,416 - $114,399	2,953 Added 101.06%	5,875 $211,000
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $755 - $1,281	23 Added 0.79%	2,922 $111,000
Q1 2022 May 04, 2022	BUY	$31.97 - $41.06 $11,796 - $15,151	369 Added 14.58%	2,899 $116,000
Q1 2021 May 14, 2021	BUY	$39.51 - $51.45 $79,020 - $102,900	2,000 Added 377.36%	2,530 $105,000
Q4 2020 Feb 10, 2021	SELL	$25.81 - $43.62 $67,183 - $113,542	-2,603 Reduced 83.08%	530 $23,000
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $22,316 - $25,689	-867 Reduced 21.68%	3,133 $82,000
Q2 2020 Aug 24, 2020	BUY	$16.25 - $26.81 $65,000 - $107,240	4,000 New	4,000 $107,000

Others Institutions Holding HALO

# of Institutions

549

Shares Held

124M

Call Options Held

668K

Put Options Held

259K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.5B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Account